APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Insulin

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

Selected research

Industry Growth & Trends

Global Biosimilar Insulin Industry Growth and Trends Forecast to 2032

29 December 202594 pages

Choose your research edition.

Industry ResearchBiosimilar Insulin Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Insulin Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Biosimilar Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Insulin Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Insulin Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Biosimilar Insulin market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biosimilar Insulin market size, estimates, and forecasts are presented in terms of sales volume (K Unit) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biosimilar Insulin market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biosimilar Insulin.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biosimilar Insulin market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biosimilar Insulin Market by Company

Eli Lilly

Sanofi

Gan&Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon

Wockhardt

Biosimilar Insulin Segment by Type

Biosimilar Insulin Glargine

Biosimilar Insulin Lispro

Other

Biosimilar Insulin Segment by Distribution Channel

Hospital

Retail Pharmacy

Others

Biosimilar Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biosimilar Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Biosimilar Insulin Glargine Table 2. Major Company of Biosimilar Insulin Lispro Table 3. Major Company of Other Table 4. Global Biosimilar Insulin Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Biosimilar Insulin Sales by Type (2021-2026) & (K Unit) Table 6. Global Biosimilar Insulin Sales Market Share in Volume by Type (2021-2026) Table 7. Global Biosimilar Insulin Sales by Type (2021-2026) & (US$ Million) Table 8. Global Biosimilar Insulin Sales Market Share in Value by Type (2021-2026) Table 9. Global Biosimilar Insulin Price by Type (2021-2026) & (US$/Unit) Table 10. Global Biosimilar Insulin Sales by Type (2027-2032) & (K Unit) Table 11. Global Biosimilar Insulin Sales Market Share in Volume by Type (2027-2032) Table 12. Global Biosimilar Insulin Sales by Type (2027-2032) & (US$ Million) Table 13. Global Biosimilar Insulin Sales Market Share in Value by Type (2027-2032) Table 14. Global Biosimilar Insulin Price by Type (2027-2032) & (US$/Unit) Table 15. North America Biosimilar Insulin Sales by Type (2021-2026) & (K Unit) Table 16. North America Biosimilar Insulin Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Biosimilar Insulin Sales by Type (2021-2026) & (K Unit) Table 18. Europe Biosimilar Insulin Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Biosimilar Insulin Sales by Type (2021-2026) & (K Unit) Table 20. Asia-Pacific Biosimilar Insulin Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Biosimilar Insulin Sales by Type (2021-2026) & (K Unit) Table 22. Latin America Biosimilar Insulin Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Biosimilar Insulin Sales by Type (2021-2026) & (K Unit) Table 24. Middle East and Africa Biosimilar Insulin Sales by Type (2021-2026) & (US$ Million) Table 25. Biosimilar Insulin Industry Trends Table 26. Biosimilar Insulin Industry Drivers Table 27. Biosimilar Insulin Industry Opportunities and Challenges Table 28. Biosimilar Insulin Industry Restraints Table 29. Global Biosimilar Insulin Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Biosimilar Insulin Revenue Market Share by Company (2021-2026) Table 31. Global Biosimilar Insulin Sales by Company (2021-2026) & (K Unit) Table 32. Global Biosimilar Insulin Sales Share by Company (2021-2026) Table 33. Global Biosimilar Insulin Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Biosimilar Insulin Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Biosimilar Insulin Major Company Production Sites and Headquarters Table 36. Global Biosimilar Insulin Company, Product Type & Application Table 37. Global Biosimilar Insulin Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Biosimilar Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Biosimilar Insulin Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Biosimilar Insulin Sales by Region (2021-2026) & (K Unit) Table 42. Global Biosimilar Insulin Sales Market Share in Volume by Region (2021-2026) Table 43. Global Biosimilar Insulin Sales by Region (2021-2026) & (US$ Million) Table 44. Global Biosimilar Insulin Sales Market Share in Value by Region (2021-2026) Table 45. Global Biosimilar Insulin Sales (K Unit), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Biosimilar Insulin Sales by Region (2027-2032) & (K Unit) Table 47. Global Biosimilar Insulin Sales Market Share in Volume by Region (2027-2032) Table 48. Global Biosimilar Insulin Sales by Region (2027-2032) & (US$ Million) Table 49. Global Biosimilar Insulin Sales Market Share in Value by Region (2027-2032) Table 50. Global Biosimilar Insulin Sales (K Unit), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Biosimilar Insulin Sales by Distribution Channel (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (K Unit) Table 53. Global Biosimilar Insulin Sales Market Share in Volume by Distribution Channel (2021-2026) Table 54. Global Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (US$ Million) Table 55. Global Biosimilar Insulin Sales Market Share in Value by Distribution Channel (2021-2026) Table 56. Global Biosimilar Insulin Price by Distribution Channel (2021-2026) & (US$/Unit) Table 57. Global Biosimilar Insulin Sales by Distribution Channel (2027-2032) & (K Unit) Table 58. Global Biosimilar Insulin Sales Market Share in Volume by Distribution Channel (2027-2032) Table 59. Global Biosimilar Insulin Sales by Distribution Channel (2027-2032) & (US$ Million) Table 60. Global Biosimilar Insulin Sales Market Share in Value by Distribution Channel (2027-2032) Table 61. Global Biosimilar Insulin Price by Distribution Channel (2027-2032) & (US$/Unit) Table 62. North America Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (K Unit) Table 63. North America Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (US$ Million) Table 64. Europe Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (K Unit) Table 65. Europe Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (US$ Million) Table 66. Asia-Pacific Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (K Unit) Table 67. Asia-Pacific Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (US$ Million) Table 68. Latin America Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (K Unit) Table 69. Latin America Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (US$ Million) Table 70. Middle East and Africa Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (K Unit) Table 71. Middle East and Africa Biosimilar Insulin Sales by Distribution Channel (2021-2026) & (US$ Million) Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Eli Lilly Biosimilar Insulin Product Portfolio Table 76. Eli Lilly Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sanofi Biosimilar Insulin Product Portfolio Table 81. Sanofi Recent Development Table 82. Gan&Lee Company Information Table 83. Gan&Lee Business Overview Table 84. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Gan&Lee Biosimilar Insulin Product Portfolio Table 86. Gan&Lee Recent Development Table 87. Tonghua Dongbao Company Information Table 88. Tonghua Dongbao Business Overview Table 89. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Tonghua Dongbao Biosimilar Insulin Product Portfolio Table 91. Tonghua Dongbao Recent Development Table 92. United Laboratory Company Information Table 93. United Laboratory Business Overview Table 94. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. United Laboratory Biosimilar Insulin Product Portfolio Table 96. United Laboratory Recent Development Table 97. Geropharm Company Information Table 98. Geropharm Business Overview Table 99. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Geropharm Biosimilar Insulin Product Portfolio Table 101. Geropharm Recent Development Table 102. Biocon Company Information Table 103. Biocon Business Overview Table 104. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Biocon Biosimilar Insulin Product Portfolio Table 106. Biocon Recent Development Table 107. Wockhardt Company Information Table 108. Wockhardt Business Overview Table 109. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Wockhardt Biosimilar Insulin Product Portfolio Table 111. Wockhardt Recent Development Table 112. North America Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 113. North America Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 114. North America Biosimilar Insulin Sales Market Share by Country (2021-2026) Table 115. North America Biosimilar Insulin Sales Forecast by Country (2027-2032) & (K Unit) Table 116. North America Biosimilar Insulin Sales Market Share Forecast by Country (2027-2032) Table 117. North America Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. North America Biosimilar Insulin Market Size by Country (2021-2026) & (US$ Million) Table 119. North America Biosimilar Insulin Market Share by Country (2021-2026) Table 120. North America Biosimilar Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. North America Biosimilar Insulin Market Share Forecast by Country (2027-2032) Table 122. Europe Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 123. Europe Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 124. Europe Biosimilar Insulin Sales Market Share by Country (2021-2026) Table 125. Europe Biosimilar Insulin Sales Forecast by Country (2027-2032) & (K Unit) Table 126. Europe Biosimilar Insulin Sales Market Share Forecast by Country (2027-2032) Table 127. Europe Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Europe Biosimilar Insulin Market Size by Country (2021-2026) & (US$ Million) Table 129. Europe Biosimilar Insulin Market Share by Country (2021-2026) Table 130. Europe Biosimilar Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Europe Biosimilar Insulin Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 134. Asia-Pacific Biosimilar Insulin Sales Market Share by Country (2021-2026) Table 135. Asia-Pacific Biosimilar Insulin Sales Forecast by Country (2027-2032) & (K Unit) Table 136. Asia-Pacific Biosimilar Insulin Sales Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Biosimilar Insulin Market Size by Country (2021-2026) & (US$ Million) Table 139. Asia-Pacific Biosimilar Insulin Market Share by Country (2021-2026) Table 140. Asia-Pacific Biosimilar Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Asia-Pacific Biosimilar Insulin Market Share Forecast by Country (2027-2032) Table 142. Latin America Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 143. Latin America Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 144. Latin America Biosimilar Insulin Sales Market Share by Country (2021-2026) Table 145. Latin America Biosimilar Insulin Sales Forecast by Country (2027-2032) & (K Unit) Table 146. Latin America Biosimilar Insulin Sales Market Share Forecast by Country (2027-2032) Table 147. Latin America Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Latin America Biosimilar Insulin Market Size by Country (2021-2026) & (US$ Million) Table 149. Latin America Biosimilar Insulin Market Share by Country (2021-2026) Table 150. Latin America Biosimilar Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Latin America Biosimilar Insulin Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 154. Middle East and Africa Biosimilar Insulin Sales Market Share by Country (2021-2026) Table 155. Middle East and Africa Biosimilar Insulin Sales Forecast by Country (2027-2032) & (K Unit) Table 156. Middle East and Africa Biosimilar Insulin Sales Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Biosimilar Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Biosimilar Insulin Market Size by Country (2021-2026) & (US$ Million) Table 159. Middle East and Africa Biosimilar Insulin Market Share by Country (2021-2026) Table 160. Middle East and Africa Biosimilar Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Middle East and Africa Biosimilar Insulin Market Share Forecast by Country (2027-2032) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Biosimilar Insulin Distributors List Table 165. Biosimilar Insulin Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. Biosimilar Insulin Image Figure 2. Global Biosimilar Insulin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Insulin Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Insulin Sales (2021-2032) & (K Unit) Figure 5. Biosimilar Insulin Glargine Image Figure 6. Global Biosimilar Insulin Glargine Sales YoY Growth (2021-2032) & (K Unit) Figure 7. Biosimilar Insulin Lispro Image Figure 8. Global Biosimilar Insulin Lispro Sales YoY Growth (2021-2032) & (K Unit) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (K Unit) Figure 11. Global Biosimilar Insulin Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Biosimilar Insulin Market Share by Type 2025 VS 2032 Figure 13. North America Biosimilar Insulin Sales Market Share in Volume by Type in 2025 Figure 14. North America Biosimilar Insulin Sales Market Share in Value by Type in 2025 Figure 15. Europe Biosimilar Insulin Sales Market Share in Volume by Type in 2025 Figure 16. Europe Biosimilar Insulin Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Biosimilar Insulin Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Biosimilar Insulin Sales Market Share in Value by Type in 2025 Figure 19. Latin America Biosimilar Insulin Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Biosimilar Insulin Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Biosimilar Insulin Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Biosimilar Insulin Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Biosimilar Insulin Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (K Unit) Figure 27. Retail Pharmacy Image Figure 28. Global Retail Pharmacy Sales YoY Growth (2021-2032) & (K Unit) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (K Unit) Figure 31. Global Biosimilar Insulin Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Biosimilar Insulin Market Share by Application 2025 VS 2032 Figure 33. North America Biosimilar Insulin Sales Market Share in Volume by Application in 2025 Figure 34. North America Biosimilar Insulin Sales Market Share in Value by Application in 2025 Figure 35. Europe Biosimilar Insulin Sales Market Share in Volume by Application in 2025 Figure 36. Europe Biosimilar Insulin Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Biosimilar Insulin Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Biosimilar Insulin Sales Market Share in Value by Application in 2025 Figure 39. Latin America Biosimilar Insulin Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Biosimilar Insulin Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Biosimilar Insulin Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Biosimilar Insulin Sales Market Share in Value by Application in 2025 Figure 43. North America Biosimilar Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 44. North America Biosimilar Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Biosimilar Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Biosimilar Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 48. Europe Biosimilar Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Biosimilar Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Biosimilar Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 52. Asia-Pacific Biosimilar Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Biosimilar Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Biosimilar Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 56. Latin America Biosimilar Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Biosimilar Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Biosimilar Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 60. Middle East and Africa Biosimilar Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Biosimilar Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Biosimilar Insulin Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Biosimilar Insulin Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Biosimilar Insulin Glargine
  • Biosimilar Insulin Lispro
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • Eli Lilly
  • Sanofi
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory
  • Geropharm
  • Biocon
  • Wockhardt

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilar Insulin Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biosimilar Insulin Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biosimilar Insulin Market by Type
  6. 1.3.1 Biosimilar Insulin Glargine
  7. 1.3.2 Biosimilar Insulin Lispro
  8. 1.3.3 Other
  9. 1.4 Global Biosimilar Insulin Market Size by Type
  10. 1.4.1 Global Biosimilar Insulin Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Biosimilar Insulin Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Biosimilar Insulin Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Biosimilar Insulin Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Biosimilar Insulin Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Biosimilar Insulin Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Biosimilar Insulin Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Biosimilar Insulin Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biosimilar Insulin Industry Trends
  2. 2.2 Biosimilar Insulin Industry Drivers
  3. 2.3 Biosimilar Insulin Industry Opportunities and Challenges
  4. 2.4 Biosimilar Insulin Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biosimilar Insulin Revenue (2021-2026)
  2. 3.2 Global Top Players by Biosimilar Insulin Sales (2021-2026)
  3. 3.3 Global Top Players by Biosimilar Insulin Price (2021-2026)
  4. 3.4 Global Biosimilar Insulin Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilar Insulin Major Company Production Sites & Headquarters
  6. 3.6 Global Biosimilar Insulin Company, Product Type & Application
  7. 3.7 Global Biosimilar Insulin Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilar Insulin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilar Insulin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilar Insulin Tier 1, Tier 2, and Tier 3
4 Biosimilar Insulin Regional Status and Outlook
  1. 4.1 Global Biosimilar Insulin Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biosimilar Insulin Historic Market Size by Region
  3. 4.2.1 Global Biosimilar Insulin Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biosimilar Insulin Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biosimilar Insulin Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biosimilar Insulin Forecasted Market Size by Region
  7. 4.3.1 Global Biosimilar Insulin Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biosimilar Insulin Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biosimilar Insulin Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biosimilar Insulin by Application
  1. 5.1 Biosimilar Insulin Market by Distribution Channel
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Biosimilar Insulin Market Size by Distribution Channel
  6. 5.2.1 Global Biosimilar Insulin Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Biosimilar Insulin Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Biosimilar Insulin Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Distribution Channel
  10. 5.3.1 North America Biosimilar Insulin Sales Breakdown by Distribution Channel (2021-2026)
  11. 5.3.2 Europe Biosimilar Insulin Sales Breakdown by Distribution Channel (2021-2026)
  12. 5.3.3 Asia-Pacific Biosimilar Insulin Sales Breakdown by Distribution Channel (2021-2026)
  13. 5.3.4 South America Biosimilar Insulin Sales Breakdown by Distribution Channel (2021-2026)
  14. 5.3.5 Middle East and Africa Biosimilar Insulin Sales Breakdown by Distribution Channel (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly
  2. 6.1.1 Eli Lilly Company Information
  3. 6.1.2 Eli Lilly Business Overview
  4. 6.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
  6. 6.1.5 Eli Lilly Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Biosimilar Insulin Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Gan&Lee
  14. 6.3.1 Gan&Lee Company Information
  15. 6.3.2 Gan&Lee Business Overview
  16. 6.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
  18. 6.3.5 Gan&Lee Recent Developments
  19. 6.4 Tonghua Dongbao
  20. 6.4.1 Tonghua Dongbao Company Information
  21. 6.4.2 Tonghua Dongbao Business Overview
  22. 6.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
  24. 6.4.5 Tonghua Dongbao Recent Developments
  25. 6.5 United Laboratory
  26. 6.5.1 United Laboratory Company Information
  27. 6.5.2 United Laboratory Business Overview
  28. 6.5.3 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 United Laboratory Biosimilar Insulin Product Portfolio
  30. 6.5.5 United Laboratory Recent Developments
  31. 6.6 Geropharm
  32. 6.6.1 Geropharm Company Information
  33. 6.6.2 Geropharm Business Overview
  34. 6.6.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Geropharm Biosimilar Insulin Product Portfolio
  36. 6.6.5 Geropharm Recent Developments
  37. 6.7 Biocon
  38. 6.7.1 Biocon Company Information
  39. 6.7.2 Biocon Business Overview
  40. 6.7.3 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Biocon Biosimilar Insulin Product Portfolio
  42. 6.7.5 Biocon Recent Developments
  43. 6.8 Wockhardt
  44. 6.8.1 Wockhardt Company Information
  45. 6.8.2 Wockhardt Business Overview
  46. 6.8.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Wockhardt Biosimilar Insulin Product Portfolio
  48. 6.8.5 Wockhardt Recent Developments
7 North America by Country
  1. 7.1 North America Biosimilar Insulin Sales by Country
  2. 7.1.1 North America Biosimilar Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biosimilar Insulin Sales by Country (2021-2026)
  4. 7.1.3 North America Biosimilar Insulin Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biosimilar Insulin Market Size by Country
  6. 7.2.1 North America Biosimilar Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biosimilar Insulin Market Size by Country (2021-2026)
  8. 7.2.3 North America Biosimilar Insulin Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biosimilar Insulin Sales by Country
  2. 8.1.1 Europe Biosimilar Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biosimilar Insulin Sales by Country (2021-2026)
  4. 8.1.3 Europe Biosimilar Insulin Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biosimilar Insulin Market Size by Country
  6. 8.2.1 Europe Biosimilar Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biosimilar Insulin Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biosimilar Insulin Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biosimilar Insulin Sales by Country
  2. 9.1.1 Asia-Pacific Biosimilar Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biosimilar Insulin Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biosimilar Insulin Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biosimilar Insulin Market Size by Country
  6. 9.2.1 Asia-Pacific Biosimilar Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biosimilar Insulin Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biosimilar Insulin Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biosimilar Insulin Sales by Country
  2. 10.1.1 South America Biosimilar Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biosimilar Insulin Sales by Country (2021-2026)
  4. 10.1.3 South America Biosimilar Insulin Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biosimilar Insulin Market Size by Country
  6. 10.2.1 South America Biosimilar Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biosimilar Insulin Market Size by Country (2021-2026)
  8. 10.2.3 South America Biosimilar Insulin Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biosimilar Insulin Sales by Country
  2. 11.1.1 Middle East and Africa Biosimilar Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biosimilar Insulin Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biosimilar Insulin Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biosimilar Insulin Market Size by Country
  6. 11.2.1 Middle East and Africa Biosimilar Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biosimilar Insulin Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biosimilar Insulin Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biosimilar Insulin Value Chain Analysis
  2. 12.1.1 Biosimilar Insulin Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biosimilar Insulin Production Mode & Process
  7. 12.2 Biosimilar Insulin Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biosimilar Insulin Distributors
  10. 12.2.3 Biosimilar Insulin Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst